Increasing epidemiological and clinical studies suggest that metabolic syndrome (MetS) plays a role in the incidence and progression of osteoarthritis (OA).1 2 However, in absence of an appropriate MetS-associated OA experimental model,3 the MetS contribution to the joint phenotype in OA remains difficult to investigate and the evaluation of potential disease-modifying OA drugs (DMOADs) is complicated. Noteworthy, in contrast to their lean SHHF+/+(spontaneously hypertensive heart failure) controls, obese SHHFcp/cp rats, a well-characterised model of MetS,4 develop drastic metabolic, cardiovascular and renal alterations that are substantially improved through an early chronic mineralocorticoid receptor antagonism (MRA) treatment.5 Thus, by comparing young (1.5 months) and aged (12.5 months) lean SHHF+/+ and obese SHHFcp/cp rats, we sought to evaluate for the first time the potential (1) contribution of MetS to joint alterations and (2) therapeutic benefits derived from chronic MRA treatment by eplerenone (figure 1A). Figure 1 Preventive 11-month treatment with mineralocorticoid receptor antagonist eplerenone alleviated the metabolic syndrome (MetS)-associated joint lesions in SHHF model. (A) Experimental design of the study. Lean spontaneously hypertensive heart failure (SHHF+/+) and obese SHHFcp/cp rats were divided randomly into treatment groups. Untreated groups (n=4 for SHHF+/+ and n=4 for SHHFcp/cp) were given …

中文翻译：

---

依普利酮治疗减轻自发性代谢相关骨关节炎新大鼠模型中关节病变的发展

越来越多的流行病学和临床研究表明，代谢综合征 (MetS) 在骨关节炎 (OA) 的发病率和进展中起作用。1 2 然而，在缺乏适当的 MetS 相关 OA 实验模型的情况下，3 MetS 对关节表型的贡献OA 中的 OA 仍然难以研究，潜在的疾病缓解 OA 药物 (DMOAD) 的评估很复杂。值得注意的是，与瘦 SHHF+/+（自发性高血压性心力衰竭）对照相比，肥胖的 SHHFcp/cp 大鼠是一种充分表征的 MetS 模型，4 发生剧烈的代谢、心血管和肾脏改变，这些改变通过早期慢性盐皮质激素得到显着改善受体拮抗剂 (MRA) 治疗。 5 因此，通过比较年轻（1.5 个月）和老年（12.5 个月）瘦 SHHF+/+ 和肥胖 SHHFcp/cp 大鼠，我们首次试图评估 MetS 对关节改变的潜在作用 (1) 和 (2) 依普利酮慢性 MRA 治疗带来的治疗益处（图 1A）。图 1 盐皮质激素受体拮抗剂依普利酮预防性治疗 11 个月缓解了 SHHF 模型中代谢综合征 (MetS) 相关的关节病变。(A) 研究的实验设计。瘦的自发性高血压心力衰竭（SHHF+/+）和肥胖的SHHFcp/cp大鼠随机分为治疗组。给予未治疗组（SHHF+/+ n=4，SHHFcp/cp n=4）…… 图 1 盐皮质激素受体拮抗剂依普利酮预防性治疗 11 个月缓解了 SHHF 模型中代谢综合征 (MetS) 相关的关节病变。(A) 研究的实验设计。瘦的自发性高血压心力衰竭（SHHF+/+）和肥胖的SHHFcp/cp大鼠随机分为治疗组。给予未治疗组（SHHF+/+ n=4，SHHFcp/cp n=4）…… 图 1 盐皮质激素受体拮抗剂依普利酮预防性治疗 11 个月缓解了 SHHF 模型中代谢综合征 (MetS) 相关的关节病变。(A) 研究的实验设计。瘦弱自发性高血压心力衰竭 (SHHF+/+) 和肥胖 SHHFcp/cp 大鼠随机分为治疗组。给予未治疗组（SHHF+/+ n=4，SHHFcp/cp n=4）……